Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual 2021 | Ven-based salvage followed by ven and DLI maintenance vs. FLAG-ida for R/R AML post-ASCT

Andrius Zucenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses venetoclax-based salvage therapy followed by venetoclax and donor lymphocyte infusion (DLI) maintenance vs. fludarabine, cytarabine, G-CSF and idarubicin (FLAG-ida) for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) after allogeneic stem cell transplantation (ASCT).